Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics (NASDAQ:KLRS) Director Srinivas Akkaraju Buys 479,847 Shares of Stock

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Kalaris to Participate at Stifel Ophthalmology Forum

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Kalaris Announces Closing of Merger with AlloVir